Cancer Biomarkers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32

1
Global Cancer Biomarkers Market Research and
Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Cancer Biomarkers Market Global Industry
  Trends, Share, Size, Growth, Opportunity and
  Forecast 2024-2032," the global cancer biomarkers
  market size reached US 27.9 Billion in 2023.
• Cancer biomarkers refer to biological molecules
  produced by the cancer cells or other cells in
  the body in response to cancer. Enzymes,
  peptides, proteins, nucleic acids, genes, and
  specific cells are some of the most commonly used
  biomarkers. They indicate the presence of cancer
  in the blood, tissues, or other fluids of the
  body.
• They are widely used for disease diagnosis,
  screening, establishing prognosis, monitoring
  treatment, and detecting the chances of relapse.
  They also assist healthcare professionals in
  tracking the progression of the disease,
  identifying invasive and non-invasive tumors, and
  recording treatment efficacy. As a result, cancer
  biomarkers find extensive applications as
  prognostics, surrogate endpoints, diagnostics,
  and personalized medicines across the healthcare
  industry.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/cancer-biomarkers-marke
  t/requestsample

4
Report Description

• Global Cancer Biomarkers Market Trends
• The rising incidences of cancer, such as breast,
  prostate, cervical, lung, and colorectal cancer,
  represent the primary factor driving the market
  growth. Besides this, the increasing usage of
  cancer biomarkers in early cancer detection,
  managing treatment, and predicting accurate
  outcomes is another major growth-inducing factor.
  Additionally, due to the lack of standard
  diagnosis, there has been a significant shift
  toward personalized medicine for cancer
  treatment. In line with this, the growing
  awareness regarding the importance of early
  cancer diagnosis among healthcare professionals
  and patients has augmented the demand for cancer
  biomarkers. Furthermore, several key players are
  extensively investing in research and development
  (RD) activities to introduce innovative
  diagnostic products.
• Along with this, recent technological
  advancements in genetic biomarker discovery, such
  as next-generation sequencing (NGS), polymerase
  chain reaction (PCR), gene expression profiling
  (microarray), and proteomics, have propelled
  market growth. Other factors, including the
  rising regulatory approvals of novel drugs and
  diagnostics, improving healthcare infrastructure,
  surging government funding for drug development,
  increasing consumer healthcare spending, and
  availability of favorable reimbursement policies,
  are also providing a positive thrust to the
  market growth.
• Looking forward, the market to reach US 77.0
  Billion by 2032, expanding at a CAGR of 11.7
  during 2024-2032
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/cancer-biomarkers-marke
  t

5
Report Segmentation

• Breakup by Profiling Technology
• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics
• Breakup by Biomolecule
• Genetic Biomarkers
• Protein Biomarkers
• Glyco-Biomarkers
• Breakup by Cancer Type
• Breast Cancer
• Lung Cancer
• Colorectal Cancer

6
Report Segmentation

• Prostate Cancer
• Stomach Cancer
• Others
• Breakup by Application
• Diagnostics
• Prognostics
• Risk Assessment
• Drug Discovery and Development
• Others
• Breakup by End User
• Hospitals
• Academic and Research Institutions

7
Report Segmentation

• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others
• Breakup by Region
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

8
Competitive Landscape with Key Players

• Abbott Laboratories
• Agilent Technologies Inc.
• Becton Dickinson and Company
• bioMérieux SA
• Danaher Corporation
• F. Hoffmann-La Roche AG
• General Electric Company
• Illumina Inc.
• Qiagen N.V.
• Sino Biological Inc.
• Thermo Fisher Scientific Inc.

9
Key Questions Answered in the Report
10
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Cancer Biomarkers
  Market    5.1    Market Overview    5.2  
   Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by Profiling Technology   
  6.1    Omic Technologies        6.1.1 Market
  Trends        6.1.2 Market Forecast    6.2  
   Imaging Technologies        6.2.1 Market
  Trends        6.2.2 Market Forecast    6.3  
   Immunoassays        6.3.1 Market Trends       
  6.3.2 Market Forecast       

11
Table of Contents

•     6.4    Cytogenetics        6.4.1 Market
  Trends        6.4.2 Market Forecast7   Market
  Breakup by Biomolecule    7.1    Genetic
  Biomarkers        7.1.1 Market Trends       
  7.1.2 Market Forecast    7.2    Protein
  Biomarkers        7.2.1 Market Trends       
  7.2.2 Market Forecast    7.3  
   Glyco-Biomarkers        7.3.1 Market Trends   
      7.3.2 Market Forecast8   Market Breakup by
  Cancer Type    8.1    Breast Cancer       
  8.1.1 Market Trends        8.1.2 Market
  Forecast    8.2    Lung Cancer        8.2.1
  Market Trends        8.2.2 Market Forecast   
  8.3    Colorectal Cancer        8.3.1 Market
  Trends        8.3.2 Market Forecast    8.4  
   Prostate Cancer        8.4.1 Market Trends   
      8.4.2 Market Forecast
•     8.5    Stomach Cancer        8.5.1 Market
  Trends        8.5.2 Market Forecast
• For more information, visit https//www.imarcgrou
  p.com/cancer-biomarkers-market/toc

12
Disclaimer

• 2023 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

13
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE [phone] E-MAIL
sales_at_imarcgroup.com